Atrovent
(Ipratropium bromide)ApprovedSmall molecule
Boehringer IngelheimIpratropium bromide is used to treat breathing problems in people with chronic obstructive pulmonary disease (COPD) and asthma by relaxing the muscles around the airways to make breathing easier.[2] Atrovent is currently approved and in use across 9 indications[4].[1]
Atrovent is one of 129 small molecule programs targeting Interstitial Lung Disease. It is currently in Approved.
9
Indications
25
Total Trials
2
Active Trials
128
Competitors
5
FDA Applications
NDA/BLA/ANDA regulatory filings
Pipeline
Status by Indication[4][1]
Indication
Competition
Competitive Landscape
45 competitors in Atopic Eczema
#DrugCompanyPhaseTrials
1Atrovent
Boehringer IngelheimApproved
Trexall
Jazz PharmaceuticalsApproved
Rinvoq
AbbVieApproved
Daliresp
AstraZenecaApproved
Revia
TevaApproved
Jakafi
IncyteApproved
Cibinqo
PfizerApproved
Calciferol
Jazz PharmaceuticalsApproved
Neoral
NovartisApproved
Anzupgo
Jazz PharmaceuticalsApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Chronic Obstructive Pulmonary Disease5 trials
Asthma5 trials
Budesonide Inhalation Suspension for Acute Asthma in Children
Completed·—·Phase 4·NCT00393367·179 enrolled
Show 2 more trials
Nebulized Magnesium Sulfate as an Adjunct to Standard Therapy in Asthma Exacerbation
Unknown status·HHospital General Naval de Alta Especialidad - Escuela Medico Naval·Phase 4·NCT02584738·152 enrolled
ESS1 trial
Interstitial Lung Disease1 trial
12 more indications
Corticosteroids1 trial
Effectiveness1 trial
Familial dysautonomia1 trial
Airway obstruction1 trial
COPD Exacerbation1 trial
Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD): A Phase IV, Prospective, Randomized, Blinded, Parallel-group Trial
Not yet recruiting·UUniversity of Tennessee Graduate School of Medicine·Approved·NCT07721922·280 enrolled
Unspecified1 trial
Regulatory
FDA Approval Timeline[5]
Dec 29, 1986
ATROVENT
NDA NDA019085
Sep 29, 1993
ATROVENT
NDA NDA020228
Oct 20, 1995
ATROVENT
NDA NDA020393
Oct 20, 1995
ATROVENT
NDA NDA020394
Nov 27, 2004
ATROVENT HFA
NDA NDA021527
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Atrovent drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Ipratropium bromide. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Muscarinic Acetylcholine Receptor M3 Antagonist[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company